127 related articles for article (PubMed ID: 23522321)
1. [Tumor markers in colorectal cancer].
Menéndez-Sánchez P; Villarejo-Campos P; Padilla-Valverde D; Menéndez-Rubio JM; Rodríguez-Montes JA
Cir Cir; 2013; 81(2):169-75. PubMed ID: 23522321
[TBL] [Abstract][Full Text] [Related]
2. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676
[TBL] [Abstract][Full Text] [Related]
3. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
4. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
[TBL] [Abstract][Full Text] [Related]
5. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
Duffy MJ; van Dalen A; Haglund C; Hansson L; Holinski-Feder E; Klapdor R; Lamerz R; Peltomaki P; Sturgeon C; Topolcan O
Eur J Cancer; 2007 Jun; 43(9):1348-60. PubMed ID: 17512720
[TBL] [Abstract][Full Text] [Related]
6. Early detection of colorectal cancer: from conventional methods to novel biomarkers.
Vatandoost N; Ghanbari J; Mojaver M; Avan A; Ghayour-Mobarhan M; Nedaeinia R; Salehi R
J Cancer Res Clin Oncol; 2016 Feb; 142(2):341-51. PubMed ID: 25687380
[TBL] [Abstract][Full Text] [Related]
7. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
Gebauer G; Müller-Ruchholtz W
Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
9. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
10. [Fecal Biomarker for Colorectal Cancer Diagnosis].
Koga Y; Yamazaki N; Matsumura Y
Rinsho Byori; 2015 Mar; 63(3):361-8. PubMed ID: 26524859
[TBL] [Abstract][Full Text] [Related]
11. Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals.
Calistri D; Rengucci C; Casadei Gardini A; Frassineti GL; Scarpi E; Zoli W; Falcini F; Silvestrini R; Amadori D
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2647-54. PubMed ID: 20929882
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of fecal cytokeratin 19 is associated with prognosis in older colorectal cancer patients.
Yang RN; Yang SH; Chang CC; Chien CC; Pan S; Huang CJ
Genet Test Mol Biomarkers; 2010 Oct; 14(5):703-8. PubMed ID: 20854102
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of CEA and CA 19-9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer.
Lee IK; Kim DH; Gorden DL; Lee YS; Sung NY; Park GS; Kim HJ; Kang WK; Park JK; Ahn CH; Kim JG; Jeon HM; Oh ST
Ann Surg Oncol; 2009 Apr; 16(4):861-70. PubMed ID: 19189191
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite analysis of fecal DNA for colorectal cancer detection.
Koshiji M; Yonekura Y; Saito T; Yoshioka K
J Surg Oncol; 2002 May; 80(1):34-40. PubMed ID: 11967905
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum levels of the carcinoembryonic antigen in hereditary non-polyposis colorectal cancer compared to levels in sporadic colorectal cancer.
Schiemann U; Günther S; Gross M; Henke G; Müller-Koch Y; König A; Muders M; Folwaczny C; Mussack T; Holinski-Feder E
Cancer Detect Prev; 2005; 29(4):356-60. PubMed ID: 16122885
[TBL] [Abstract][Full Text] [Related]
17. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
18. [The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].
Iarŭmov N; Ignatov A; Viiachki I
Khirurgiia (Sofiia); 1998; 51(3):42-8. PubMed ID: 9974027
[TBL] [Abstract][Full Text] [Related]
19. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
[TBL] [Abstract][Full Text] [Related]
20. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
